BioAdvance is a venture capital firm investing in early-stage life sciences companies and technologies in the mid-Atlantic region. BioAdvance CEO Barbara Schilberg expands on her over three decade career in biotech from serving as general counsel and running clinical trials at several biotech companies to now being a life sciences investor. During her tenure, BioAdvance has invested over $49 million in 93 companies and academic technologies, which have attracted $3 billion in capital. In our conversation, Barbara outlines qualities vital for a successful entrepreneur and encourages women to challenge the assumption that entrepreneurship is only for young folks.
